The “financial toxicity” posed by very expensive cancer therapies was a major talking point at the recent American Society of Clinical Oncology (ASCO) meeting. And in May the World Health Organisation’s major forum on fair pricing of medicines concluded that governments must play a stronger role in setting prices and R&D priorities. The forum called for much greater transparency on drug pricing, along with a move away from value-based pricing and removal of the link between p